文献速递免疫规划妇幼与学校卫生慢病防控与筛查

孕期RSV疫苗接种预防儿童反复喘息随机临床试验的样本量分析

Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: A sample size analysis.
PubMed 文献 · Vaccine · 2018-11-22

研究基于系统综述与荟萃分析参数,计算母体RSV疫苗试验检测儿童反复喘息减少所需样本量。在57个更合理场景中,最低需每组6196对母婴,但75%和47%场景分别需超过31060和100000对母婴。结论认为为上市开展的母体RSV疫苗效力试验难以证明对反复喘息的效果。

要点

  • 70%场景中接种与反复喘息的危险比在0.9至1.0之间。
  • 更合理场景中最低样本量为每组6196对母婴。
  • 多数合理场景需每组超过31060对母婴,试验可行性低。

核心结论

  • 为上市开展的候选母体RSV疫苗临床效力试验不太可能证明对儿童反复喘息疾病的效果。
  • 需要进一步努力规划替代研究设计以估计母体RSV疫苗项目对一般人群儿童反复喘息的影响。

研究设计与样本

  • 研究为样本量分析,模型输入来自系统综述和荟萃分析。
  • 计算取决于疫苗效力、分配比、早期严重RSV疾病率、3岁时反复喘息风险及RSV感染对反复喘息风险增加等参数的疫苗试验效应量。

主要发现

  • 在81个1:1分配比场景中,70%场景的接种与反复喘息危险比范围为0.9至1.0。
  • 在57个更合理场景中,检测反复喘息显著减少所需最低样本量为每组6196对母婴。
  • 在更合理场景中,75%需每组超过31060对母婴,47%需每组超过100000对母婴。
  • 以5岁时哮喘为终点研究可能需要更大样本量。

临床怎么用

  • 提示临床医生母体RSV疫苗试验以反复喘息为终点需极大样本量,现有许可试验难以评估该结局。
  • 支持规划替代研究设计评估母体RSV疫苗对儿童反复喘息的群体影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early RSV illness is associated with wheeze-associated disorders in childhood. Candidate respiratory syncytial virus (RSV) vaccines may prevent acute RSV illness in infants. We investigated the feasibility of maternal RSV vaccine trials to demonstrate reductions in recurrent childhood wheezing in general paediatric populations. METHODS: We calculated vaccine trial effect sizes that depended on vaccine efficacy, allocation ratio, rate of early severe RSV illness, risk of recurrent wheezing at age 3, and increased risk of RSV infection on recurrent wheezing. Model inputs came from systematic reviews and meta-analyses. For each combination of inputs, we estimated the sample size required to detect the effect of vaccination on recurrent wheezing. RESULTS: There were 81 scenarios with 1:1 allocation ratio. Risk ratios between vaccination and recurrent wheezing ranged from 0.9 to 1.0 for 70% of the scenarios. Among the 57 more plausible scenarios, the lowest sample size required to detect significant reductions in recurrent wheezing was 6196 mother-infant pairs per trial arm; however, 75% and 47% of plausible scenarios required >31,060 and >100,000 mother-infant pairs per trial arm, respectively. Studies with asthma endpoints at age 5 will likely need to be larger. DISCUSSION: Clinical efficacy trials of candidate maternal RSV vaccines undertaken for licensure are unlikely to demonstrate an effect on recurrent wheezing illness due to the large sample sizes likely needed to demonstrate a significant effect. Further efforts are needed to plan for alternative study designs to estimate the impact of maternal RSV vaccine programs on recurrent childhood wheezing in general populations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Riddell CA, Bhat N, Bont LJ, et al. Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: A sample size analysis. Vaccine. 2018. PMID: 30473186. doi:10.1016/j.vaccine.2018.10.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。